NEW YORK (GenomeWeb) – Thermo Fisher Scientific and French firm Cellectis have inked a series of agreements covering the use of TAL nucleases for a variety of applications.

Under the agreements, Thermo Fisher gains a worldwide license under Cellectis' IP rights to use TAL nucleases outside the therapeutics field with exclusive rights to grant sublicenses in research and development, bioproduction, and applied markets. Thermo Fisher's Life Technologies business markets TAL nucleases under the brand name TALEN for these applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.